Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Zhou, Qing
Wu, Yi Long
Yu, Xiyong
Yang, Jinji
Wen, Limin
Sai, Yang
Mu, Hua
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
[4] Hutchison MediPharma, Shanghai, Peoples R China
[5] Hutchison Medi Pharma, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19042
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [23] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [24] Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors
    Rosen, Lee S.
    Kurzrock, Razelle
    Mulay, Marilyn
    Van Vugt, Andy
    Purdom, Michelle
    Ng, Chaan
    Silverman, Jeffrey
    Koutsoukos, Antonis
    Sun, Yu-Nien
    Bass, Michael B.
    Xu, Ren Y.
    Polverino, Anthony
    Wiezorek, Jeffrey S.
    Chang, David D.
    Benjamin, Robert
    Herbst, Roy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) : 2369 - 2376
  • [25] Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
    Toshihiko Doi
    Nobuaki Matsubara
    Akira Kawai
    Norifumi Naka
    Shunji Takahashi
    Hiroji Uemura
    Noboru Yamamoto
    Investigational New Drugs, 2020, 38 : 1175 - 1185
  • [26] Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
    Doi, Toshihiko
    Matsubara, Nobuaki
    Kawai, Akira
    Naka, Norifumi
    Takahashi, Shunji
    Uemura, Hiroji
    Yamamoto, Noboru
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1175 - 1185
  • [27] A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Schwartz, G. K.
    Robertson, S.
    Shen, A.
    Wang, E.
    Pace, L.
    Dials, H.
    Mendelson, D.
    Shannon, P.
    Gordon, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases in patients with advanced solid tumors
    Li, Jin
    Cao, Junning
    Zhang, Jian
    Fan, Songhua
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Shinji Nakamichi
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Kazunori Honda
    Yosuke Tamura
    Hiroshi Wakui
    Tatsuya Sasaki
    Wataru Yusa
    Katsuki Fujino
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1153 - 1161
12345